Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Researcher Calls for Less Toxic HIV Therapy
Uncategorized

Researcher Calls for Less Toxic HIV Therapy

By medwebJul 1, 2002
Share
Facebook Twitter Email

July 8, 2002

Researcher Calls for Less Toxic HIV Therapy

BARCELONA— A Northwestern University researcher today called on HIV researchers and clinicians to develop more simplified and less toxic strategies to insure patient compliance and quality of life without sacrificing the potency of a protease inhibitor-containing regimen.

The current standard of care for HIV includes complicated protease inhibitor-based combination therapies with large numbers of pills and raises problems relative to drug potency, adherence, toxicity, resistance, and cost, said Robert L. Murphy, MD, at a symposium held at the XIV International AIDS Conference. Dr. Murphy is professor of medicine at The Feinberg School of Medicine and director of HIV/AIDS clinical research at Northwestern.

“Protease inhibitor-based therapies, although potent and effective, have been associated with complex regimens with dosing schedule restraints and frequent adverse events that may interfere with a patient’s compliance and quality of life,” he said.

Side effects reported with most currently available protease inhibitors include gastrointestinal effects, liver problems, and high levels of cholesterol and triglycerides in the blood. Protease inhibitor resistance involves the inability of the drug to retain sensitivity to other protease inhibitor-resistant virus.

“There is increasing concern that failure of the initial protease inhibitor-containing regimen will jeopardize the opportunities for patients to successfully respond to subsequent protease inhibitor therapy due to the emergence of cross-resistant virus,” Dr. Murphy said.

“Each of these factors contributes to the likelihood that a patient will not be able to tolerate or adhere to therapy,” Dr. Murphy said.

Murphy discussed potential new HIV treatments, particularly atazanavir, a single-daily-dose protease inhibitor currently undergoing clinical trials, that has been found to be well tolerated and causes virtually none of the negative effects on cholesterol and triglyeride levels associated with other protease inhibitors.

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.